Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

The FDA has approved olaparib (Lynparza) plus abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious...

Treatment with the first-in-class direct and competitive telomerase inhibitor imetelstat resulted in statistically significant and clinically meaningful efficacy in patients with heavily transfusion dependent,...

Transcript Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr. Alicia Morgans: Hi, and welcome to The ASCO...

Pembrolizumab plus chemotherapy with or without bevacizumab led to a substantial improvement in overall survival vs placebo plus chemotherapy with or without bevacizumab in...

By The ASCO Post Staff Posted: 6/3/2023 10:26:00 AM Last Updated: 6/3/2023 9:45:31 AM Patients with newly diagnosed advanced ovarian cancer without a BRCA...

Liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin generated statistically significant and clinically meaningful overall survival and progression-free survival benefits compared with gemcitabine plus nab-paclitaxel in...

Mirvetuximab soravtansine demonstrated an overall survival benefit in FRα-high, platinum-resistant ovarian cancer vs investigator’s choice...

2023 ASCO Annual Meeting Lisa A. Carey, MD, of the University of North Carolina at Chapel Hill, and Dennis J. Slamon, MD, PhD, of...

Gastrointestinal oncology experts discuss current strategies and novel developments in gastrointestinal cancers, the role of intestinal dysbiosis and gastrointestinal carcinogenesis, germline genetic features in...

2023 ASCO Annual Meeting Enrique Grande, MD, of The University of Texas MD Anderson Cancer Center, discusses new findings that show initial responses to...